The FDA issued recent updates regarding drugs that are currently in shortage or have been discontinued:
- Clonazepam Tablets (New – Discontinuation)
- Dextroamphetamine Sulfate Extended-Release Capsules (New – Discontinuation)
- Dextrose 5% Injection Bags (Updated – Currently in Shortage)
- Disulfiram Tablets (New – Discontinuation)
- Etoposide Injection (Updated – Currently in Shortage)
- Heparin Sodium and Sodium Chloride 0.9% Injection (Updated – Currently in Shortage)
- Indomethacin Capsules (New – Discontinuation)
- Lidocaine Hydrochloride (Xylocaine) and Dextrose Injection Solution-Premix Bags (Updated – Currently in Shortage)
- Metronidazole Injection, USP (Updated – Currently in Shortage)
- Morphine Sulfate Extended-Release Tablets (New – Discontinuation)
- Penicillin G Benzathine (Bicillin L-A) Injection (Updated – Resolved)
- Pentoxifylline Extended-Release Tablets (New – Discontinuation)
- Potassium Chloride Injection (Updated – Currently in Shortage)
- Sodium Chloride 0.9% Injection Bags (Updated – Currently in Shortage)
- Sterile Water (Updated – Currently in Shortage)
According to the FDA:
“A drug receives Resolved status when the Drug Shortages Staff (DSS) determines that the market is covered, based on information from all manufacturers. The market is considered covered when supply is available from at least one manufacturer to cover total market demand. However, some manufacturers may not have all presentations available. DSS monitors the supply of products with Resolved status. For the most current supply information, contact the manufacturers.”
(Source: U.S. Food & Drug Adminstration)
Follow us on Twitter and Facebook for updates on the latest pharmaceutical and biopharmaceutical manufacturing news!
